DB05750InvestigationalSmall molecule
AVE-1625 is an oral selective and potent antagonist of cannabinoid 1 (CB1) receptors having the same mechanism of action as rimonabant. It is currently developed in obesity and its associated... AVE-1625 is also being developed for the treatment of Alzheimer disease.
- Mechanism
- Curator reviewed
AVE-1625 is a selective and potent antagonist of cannabinoid 1 (CB1) receptors having the same mechanism of action as rimonabant.
- Primary indication
- Investigated for use/treatment in alzheimer's disease, obesity, and schizophrenia and schizoaffective disorders.Curator reviewed
- Code names
- AVE-1625
Resolves to
Compound
Targets
What you can answer from here — as of June 15, 2026
Which drugs share a target with Drinabant, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account